McKinstry Nancy 4

What Happened Nancy McKinstry, a director of Abbott Laboratories (ABT), received two awards on April 24, 2026: 2,286 restricted stock units (RSUs) and 2,305 option-based awards (reported as a derivative grant). Both grants were recorded at $0.00 (no cash paid), i.e., awards issued by the company rather than open-market purchases or sales.

Key Details

• Transaction date: 2026-04-24; Form 4 filed: 2026-04-28 (Accession 0001294731-26-000004).
• Awards: 2,286 RSUs @ $0.00 (award); 2,305 option-based units @ $0.00 (derivative award). Total reported value: $0 in cash consideration.
• Shares owned after transaction: Not specified in the provided summary of the filing.
• Footnotes:
  • F1: RSU award paid one-for-one in Abbott common shares on the earlier of separation of service, death, or a change in control under the Abbott 2026 Incentive Stock Program.
  • F2: Stock option granted under the Program; grant reported as exempt from Section 16 short-swing liability under Rule 16b-3 (typical for director awards).
• Filing timeliness: The Form 4 lists the trade date and was filed four days later; the filing does not indicate a late-report flag.

Context RSU and option grants to non-employee directors are common as part of routine compensation and do not involve an immediate market purchase or sale. The RSUs convert to common shares only upon specified events (e.g., separation, death, or change in control). The option/derivative grant is a standard equity award under the company program and was reported as exempt under Rule 16b-3. These awards are compensation events rather than direct signals of buying or selling stock.